Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Intra-Cellular Therapies Inc has a consensus price target of $91.31 based on the ratings of 16 analysts. The high is $130 issued by Cantor Fitzgerald on September 16, 2024. The low is $70 issued by SVB Leerink on April 21, 2022. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Piper Sandler, and JP Morgan on September 16, 2024, September 6, 2024, and August 21, 2024, respectively. With an average price target of $101 between Cantor Fitzgerald, Piper Sandler, and JP Morgan, there's an implied 35.21% upside for Intra-Cellular Therapies Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Intra-Cellular Therapies (NASDAQ:ITCI) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $130.00 expecting ITCI to rise to within 12 months (a possible 74.03% upside). 44 analyst firms have reported ratings in the last year.
The latest analyst rating for Intra-Cellular Therapies (NASDAQ:ITCI) was provided by Cantor Fitzgerald, and Intra-Cellular Therapies reiterated their overweight rating.
The last upgrade for Intra-Cellular Therapies Inc happened on September 6, 2024 when Piper Sandler raised their price target to $92. Piper Sandler previously had a neutral for Intra-Cellular Therapies Inc.
The last downgrade for Intra-Cellular Therapies Inc happened on June 25, 2024 when UBS changed their price target from $85 to $83 for Intra-Cellular Therapies Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.
While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a reiterated with a price target of $130.00 to $130.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $74.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.